Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Suissa, Samy ^a   Dell’Aniello, Sophie ^a   Ernst, Pierre ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE;

ALGORITHM; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPLICATION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALGORITHMS; ARRHYTHMIAS, CARDIAC; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; HEART FAILURE; HUMANS; MUSCARINIC ANTAGONISTS; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; RISK FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85043518726     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02245-2016     Document Type: Article

References (32)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–1276.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555.
3. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
4. Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013; 68: 114–116.
5. Lahousse L, Verhamme KM, Stricker BH, et al. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4: 149–164.
6. Jara M, Wentworth C III, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open 2012; 2: e000841.
7. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173: 1175–1185.
8. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–1103.
9. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic review. Chest 2012; 142: 1104–1110.
10. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524–533.
11. Suissa S, Dellaniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. Chest 2017; 151: 60–67.
12. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J 2015; 45: 969–979.
13. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 2016; 374: 2222–2234.
14. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686–689.
15. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4–14.
16. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 44: 827–836.
17. Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf 2016; doi: 10.1002/pds.4107.
18. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009; 20: 512–522.
19. Hammad TA, McAdams MA, Feight A, et al. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008; 17: 1197–1201.
20. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950–1957.
21. Renoux C, Dell’Aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case–control study. Br Med J 2010; 340: c2519.
22. Renoux C, Dell’Aniello S, Brophy JM, et al. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf 2012; 21: 34–41.
23. Filion KB, Joseph L, Boivin JF, et al. Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2011; 20: 785–796.
24. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128–e136.
25. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563–568.
26. Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: Part 1: Saskatchewan Cohort Study. Chest 2012; 142: 298–304.
27. Wilchesky M, Ernst P, Brophy JM, et al. Bronchodilator use and the risk of arrhythmia in COPD: Part 2: Reassessment in the Larger Quebec Cohort. Chest 2012; 142: 305–311.
28. Resources for professionals: QT drug lists by risk group. https://crediblemeds.org/new-drug-list Date last accessed: March 14, 2017.
29. Rodriguez-Roisin R. COPD exacerbations. 5: Management. Thorax 2006; 61: 535–544.
30. Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case–control studies. Am J Med 1980; 68: 255–258.
31. Halpin DM, Dahl R, Hallmann C, et al. Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis 2015; 10: 239–259.
32. Miettinen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989; 42: 325–331.